Max Goldstein

Max Goldstein is the Vice President of Research Partnerships at xCures, a technology platform focusing on connecting advanced cancer patients with necessary drugs and tests.

xCures offers personalized treatment options curated by expert scientists and oncologists, and patients provide their data along with signed HIPAA release for medical record access.

The platform facilitates pharmaceutical companies in making investigational and existing drugs available to patients to generate valuable real-world evidence (RWE) for drug development and reimbursement purposes.

Pharmaceutical companies pay fees to access patient data, which are structured for direct use in regulatory submissions to the FDA through organized source documents.

Through managed access programs, drugs are offered to patients on the xCures platform with prospective collection of RWE by obtaining consent and medical records from doctors and hospitals.

xCures aims to enhance the experience of advanced cancer patients in the US, especially those who are unable to access clinical trials, by utilizing AI algorithms to optimize treatment options based on continuous learning from patient data.

Max Goldstein's educational background includes a Master of Health Administration from NYU Robert F. Wagner Graduate School of Public Service, as well as a BS in Health: Science, Society, and Policy & Biology, Cum Laude from Brandeis University.

Max has held various roles in the healthcare industry, including Director, US Business Development at Certara, Associate Director at Doctor Evidence, LLC, and Analyst positions at Evidera. He also served as a Market Access Intern at GfK Bridgehead.

With a wealth of experience in research partnerships and market development, Max Goldstein remains dedicated to leveraging data-driven solutions to improve cancer patient outcomes and advance drug development in the healthcare sector.